Linking axonal degeneration to microtubule remodeling by Spastin-mediated microtubule severing

Katia J. Evans,1,2 Edgar R. Gomes,1,3 Steven M. Reisenweber,1,2 Gregg G. Gundersen,1,3 and Brett P. Lauring1,2

1Department of Pathology, 2Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, and 3Department of Anatomy and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY 10032

Mutations in the AAA adenosine triphosphatase (ATPase) Spastin (SPG4) cause an autosomal dominant form of hereditary spastic paraplegia, which is a retrograde axonopathy primarily characterized pathologically by the degeneration of long spinal neurons in the corticospinal tracts and the dorsal columns. Using recombinant Spastin, we find that six mutant forms of Spastin, including three disease-associated forms, are severely impaired in ATPase activity. In contrast to a mutation designed to prevent adenosine triphosphate (ATP) binding, an ATP hydrolysis–deficient Spastin mutant predicted to remain kinetically trapped on target proteins decorates microtubules in transfected cells. Analysis of disease-associated missense mutations shows that some more closely resemble the canonical hydrolysis mutant, whereas others resemble the ATP-binding mutant. Using real-time imaging, we show that Spastin severs microtubules when added to permeabilized, cytosol-depleted cells stably expressing GFP-tubulin. Using purified components, we also show that Spastin interacts directly with microtubules and is sufficient for severing. These studies suggest that defects in microtubule severing are a cause of axonal degeneration in human disease.

Introduction

Neurons expend considerable effort maintaining and sometimes degrading axons in response to a variety of cues. Human genetic phenotypes afforded by diseases that are characterized by axonal degeneration and the study of the corresponding disease genes may shed light into the mechanisms responsible for axonal homeostasis and neurodegenerative disorders. Mutations in Spastin, an AAA ATPase that is widely expressed, are the most common cause of the autosomal dominant hereditary spastic paraplegia (Hazan et al., 1999), which is a retrograde axonopathy that primarily affects the corticospinal tracts and the fasciculus gracilis characterized clinically primarily by spastic gait (Fink, 2002).

The function of Spastin is unclear. Neuronal suppression of Drosophila melanogaster Spastin using RNAi results in undergrowth of the neuromuscular junction and increased synaptic currents, whereas overexpression results in decreased currents (Trota et al., 2004).

AAA proteins often function as oligomers, with each protomer usually containing one or two AAA ATPase modules. These domains share several key structural motifs and are homologous to some degree among all AAA proteins. NH2-terminal domains of AAA family members that bind adaptors or directly to target proteins are usually highly divergent and, therefore, are determinant of specificity of cellular function. This portion of Spastin contains an MIT domain—a domain of unknown function (Ciccarelli et al., 2003) found in several proteins that function in the endosome, including VPS4/SKD1 (an AAA ATPase involved in endosomal trafficking), and in sorting nexin 15. Interestingly, another hereditary spastic paraplegia gene, Spartin, contains an MIT domain.

Although the MIT domain mediated interaction of Spastin with the endosomal protein CHMP1B (Reid et al., 2005) raises the possibility an endosome-related function, Spastin’s AAA ATPase domain (Frohlich, 2001; Frickey and Lupas, 2004) is most homologous to those found in VPS4, Fidegtin, and Katanin, a microtubule-severing AAA ATPase (McNally and Vale, 1993). First purified from mitotic sea urchin extracts, Katanin has been shown to play a role in microtubule reorganization at the onset of mitosis (McNally and Vale, 1993; McNally and Thomas, 1998). In neurons, Katanin appears to be a source of noncentrosomal microtubules (Ahmad et al., 1999). Katanin...
overexpression in cultured mammalian neurons or in transgenic *D. melanogaster* alters process outgrowth (Karabay et al., 2004) and results in developmental abnormalities of the mushroom body (Nicolai et al., 2003), respectively.

Spastin overexpression in cultured cells or in *D. melanogaster* tissues results in decreased microtubule content (Errico et al., 2002; Sherwood et al., 2004; Trotta et al., 2004) by an unknown mechanism. Based on the homology of Spastin’s ATPase domain to that found in Katanin, Spastin has been hypothesized to have microtubule-severing activity. However, overexpression of many types of proteins including tubulin isoforms (Bhattacharya and Cabral, 2004), tubulin folding cofactors (Martin et al., 2000), and others (Antonsson et al., 1998) results in decreased microtubule content. To determine the precise mechanism by which Spastin alters microtubule content, we used video microscopic and biochemical assays to demonstrate that recombinant Spastin makes internal breaks along the lengths of microtubules both with purified in vitro assembled microtubules and when added to permeabilized cytosol extracted fibroblasts stably expressing GFP-tubulin. We show that Spastin is sufficient for severing, and that several disease-associated mutations in Spastin abolish both ATPase and severing activities.

**Results**

**Disease-associated mutations in Spastin abrogate ATPase activity**

Spastin possesses a COOH-terminal AAA module, an ~250-amino acid domain that contains several signature motifs found in AAA proteins including the Walker A and B motifs (Ogura and Wilkinson, 2001) and the arginine finger (Ogura et al., 2004). The contribution of conserved amino acids in these motifs to ATP binding and hydrolysis and enzyme oligomerization have been elucidated by structural and mutational analysis in a variety of AAA proteins. Mutation of walker A motif P-loop residues can result in enzymes that either fail to bind ATP or that bind but do not hydrolyze ATP. Arginine finger mutations can result in defects in ATP hydrolysis or in oligomerization defects (Ogura et al., 2004). Many missense mutations in Spastin change amino acids that are conserved in AAA domains including Walker A and B motifs and R-finger residues.

To determine whether the enzymatic activity of Spastin is altered by disease-associated missense mutations, many of which change conserved residues in the AAA domain (Fonknechten et al., 2000; Lindsey et al., 2000), we produced and purified recombinant GST-Spastin (Fig. 1 A). Recombinant GST-Spastin hydrolyzes ATP with a $K_m$ and $V_{max}$ in the range for those reported for other AAA ATPases (Fig. 1, B–D). None of the three disease-associated mutants tested had significant enzymatic activity (Fig. 1 E). Two of these mutations are in the P-loop (K388R and N386K), but the third involves the arginine finger motif (R499C). Removal of the NH$_2$-terminal GST tag by site-specific proteolysis did not change ATPase activity (not depicted). Q347K Spastin lacked activity (not depicted, see also Fig. 2 h). Neither Spastin, with a canonical Walker A mutation (K388A) designed to prevent ATP binding, nor Spastin harboring a Walker B (E442Q) mutation designed to allow ATP binding but prevent hydrolysis, showed any significant activity. This suggests that the measured ATPase activity with WT enzyme results from Spastin’s activity and not from contaminating ATPases.

![Figure 1](image-url)
Spastin targets microtubules in transfected cells

When overexpressed, some missense mutations cause Spastin to decorate microtubules (Errico et al., 2002). In the absence of analyzing mutations altering predicted aspects of AAA biochemistry in Spastin, the meaning of this decoration is unclear. We undertook a systematic analysis by engineering canonical mutations of conserved residues in the AAA domain with known functional consequences (i.e., by homology modeling with coordinate mutations in other AAA proteins) to better gauge the effects of the disease mutations. In particular, an E to Q mutation in the Walker B motif in many different AAA ATPases results in enzymes that bind but do not hydrolyze ATP (Ogura and Wilkinson, 2001). Because many AAA proteins bind target proteins when loaded with ATP both in vitro and in a cellular context, Walker E to Q mutations might be a useful tool to inform about the cellular target proteins of AAA proteins of unknown function. This approach has been documented to be reliable in test cases involving NSF, VCP/p97, and VPS4 (Babst et al., 1997, 1998; Ye et al., 2001, 2003; Dalal et al., 2004).

E442Q Spastin, which is predicted to bind but not hydrolyze ATP and thus remain kinetically trapped on target proteins, shows a filamentous pattern (Fig. 2b). These filaments represent a subset of microtubules and are even observed in SW cells that lack cytosolic intermediate filament proteins (Sarria et al., 1994), suggesting that the filaments are indeed microtubules (unpublished data). Furthermore, nocodazole treatment abolished this pattern of Spastin fluorescence (Errico et al., 2002; unpublished data). These results suggest that, upon ATP binding, Spastin targets to microtubules. As a negative control, we engineered a canonical Walker A motif P-loop mutation involving an invariant Lys (position 388 in Spastin). Typically, mutation of this Lys to Ala results in an enzyme that does not bind ATP (Babst et al., 1998). In contrast to E442Q Spastin, K388A Spastin does not decorate microtubules (Fig. 2f).

We analyzed six disease-associated mutations in the AAA domain of Spastin (Fig. 2, c–e and g–i), and observed the microtubule pattern with K388R, N386K, and I344K. Note that mutation of Lys 388 to Arg or Ala had different consequences (Fig. 2, compare f with c). Because K388R more closely resembled E442Q than K388A, we suggest that the K388R mutant is primarily a hydrolysis deficient enzyme. The percentage of transfected cells showing the filamentous pattern in a representative experiment is shown in Fig. 2j. We suggest that mutations showing the filamentous pattern that resemble that seen with E442Q engineered mutations are probably kinetically impaired with respect to ATP hydrolysis but bind ATP and target to microtubules. We hypothesize that mutations showing the punctate structures akin to that seen with K388A Spastin may not bind ATP at all. The locations of the mutations analyzed are shown schematically in Fig. 2k.

Consistent with the idea that microtubules are a Spastin target, overexpression of WT Spastin results in a decreased steady-state number of both dynamic and stable microtubules in transfected cells (Fig. 2a and Fig. 3, a–d) as assessed by staining with antibodies specific for either Tyr or deetyrosinated Glu-tubulin (Gundersen et al., 1984). We also examined the consequences of overexpression of representative Spastin mutants, including one that shows a primarily filamentous pattern and one that shows the punctate pattern. Compared with neighboring untransfected cells, the content and arrangement of both stable and dynamic microtubules appear relatively normal in the K388A expressing cell (Fig. 3, i–l). As seen in Fig. 2, the Spastin mutants that showed the filamentous pattern only decorated a subset of microtubules in cells, often centrally and surrounding the nucleus. To determine whether this decorated subset represents stable microtubules, we analyzed E442Q YFP-Spastin expressing by immunofluorescence microscopy using tubulin antibodies specific for Tyr and Glu tubulin. The latter antibody stains stable microtubules. In the majority of
cells examined, overexpression of E442Q Spastin results in an increased content of stable microtubules (Fig. 3 f, compare nontransfected cells with transfected cell). Often, but not in every cell, the extent of Spastin colocalization with microtubules enriched in Glu-tubulin is greater than those enriched in Tyr-tubulin. Overexpression of Spastin mutants showing the filamentous pattern also causes bundling of decorated microtubules. At least in these overexpression experiments, filamentous Spastin mutants appear to act like a MAP, in that they stabilize and bundle microtubules. Similar results were obtained when we stained for acetylated rather than Glu-tubulin and with other filamentous Spastin mutants (unpublished data).

Recombinant Spastin severs microtubules in permeabilized cells

We developed a permeabilized cell assay to visualize the effects of Spastin on microtubules. Cells were permeabilized with low concentrations of Triton X-100 to deplete cytosol before taxol-induced microtubule stabilization. Taxol was added to prevent the ATP-induced microtubule depolymerization that otherwise occurs in permeabilized cells (Infante et al., 2000). Addition of ATP and WT Spastin, but not ATP and mutant Spastin, to permeabilized TC7 cells resulted in a time-dependent decrease in microtubule content indicating that disassembly requires ATP hydrolysis by Spastin (Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb.200409058/DC1). To confirm that Spastin is responsible for the observed breaks, we imaged microtubules in real time during incubations with Spastin (Fig. 4 and Videos 1–3). Permeabilized, cytosol-depleted NIH 3T3 cells stably expressing GFP-tubulin were incubated with WT or E442Q Spastin, as indicated in the figure legend. Reactions were initiated by addition of ATP to 0.25 mM. In incubations with mutant enzyme, no loss of microtubules was observed even after 12 min (Fig. 4 g, and Video 3). In contrast, initiation of WT-containing reactions with ATP resulted in severing of nearly all microtubules in the cell (Fig. 4, a–f; and Videos 1 and 2). Once the reaction started, it proceeded rapidly with all microtubules being affected to a similar degree. Breaks (Fig. 4, e and f, arrows) seem to appear internally with no obvious preference for one end or the other of microtubules.

Spastin-mediated microtubule severing with purified components

We next used videomicroscopy to monitor severing of purified rhodamine-labeled microtubules that had been immobilized in glass perfusion chambers with an ATP hydrolysis deficient D. melanogaster (E164A) kinesin which in the presence of ATP binds to microtubules with increased affinity compared with WT enzyme (Klumpp et al., 2003). As shown in Fig. 5, WT Spastin resulted in the appearance of breaks in microtubules over the course of the experiment, whereas incubation with E442Q ATP hydrolysis–deficient Spastin (Fig. 5, h and i did not result in severing over the 32 min of the experiment). After severing, ends of microtubules were sometimes mobile with released microtubule fragments sometimes being perfused away (Videos 4 and 5, available at http://www.jcb.org/cgi/content/
In each panel, some of the new breaks are marked with arrowheads. This experiment demonstrates that ATP hydrolysis by Spastin is sufficient for microtubule severing. As expected for a severing enzyme and consistent with the transfection data in Figs. 2 and 3, we found that E442Q Spastin binds along the lengths of the immobilized microtubules (Fig. S2).

We also used an established cosedimentation assay (McNally and Vale, 1993) to ascertain whether Spastin is sufficient for microtubule severing. As expected for a severing enzyme and consistent with the transfection data in Figs. 2 and 3, we found that E442Q Spastin binds along the lengths of the immobilized microtubules (Fig. S2).

Although some AAA proteins, including Katanin, show substrate-induced increases in ATPase activity (Matveeva and Whiteheart, 1998; Hartman and Vale, 1999; Cashikar et al., 2002), we have not detected any microtubule-related change in Spastin’s activity (unpublished data). Whereas, in transfected cells, only YFP-E442Q and not YFP-K388A Spastin colocal-
Figure 6. **Spastin is sufficient for severing MTs.** Taxol-stabilized MTs were assembled from purified tubulin GTP and taxol and incubated with recombinant Spastin and nucleotides as indicated in the figure. After 10 min at 37°C, microtubules were separated from tubulin dimer by ultracentrifugation. In the absence of ATP, WT GST-Spastin sediments with microtubules (lanes 1 and 9), indicating direct binding. In contrast, with ATP, most of the tubulin was recovered in the supernatant fraction (lane 4), indicating that severing occurred. Note that Spastin does not sediment nonspecifically (lane 4). E442Q and K388A mutant Spastin sediment with microtubules but do not sever even in the presence of ATP (lanes 5 and 7). These results suggest that ATP hydrolysis is required for severing. Neither AMP-PNP nor ADP could substitute for ATP (lanes 11 and 13). The two panels represent separate experiments. (Top gel) White line indicates that AMP-PNP nor ADP could substitute for ATP (lanes 11 and 13). The two panels represent separate experiments. (Top gel) White line indicates that AMP-PNP nor ADP could substitute for ATP (lanes 11 and 13). The two panels represent separate experiments. (Top gel) White line indicates that AMP-PNP nor ADP could substitute for ATP (lanes 11 and 13). The two panels represent separate experiments. (Top gel) White line indicates that AMP-PNP nor ADP could substitute for ATP (lanes 11 and 13). The two panels represent separate experiments.

**Discussion**

We demonstrated that Spastin is a microtubule-severing enzyme that can act directly on microtubules and that several disease-associated mutations impair the enzymatic activity of Spastin. By comparison to immunofluorescence patterns obtained with canonical Walker A and Walker B mutations, we suggest that some disease-causing mutations impair ATP binding, whereas others are likely impaired at the ATP hydrolysis step of the reaction cycle.

It is currently unclear whether the two severing enzymes subserve different functions. Nevertheless, our demonstration that a second AAA ATPase is capable of microtubule severing suggests that cells use this means of regulating microtubule dynamics in a broad array of circumstances. Both Katanin and Spastin are expressed in a wide variety of neurons and nonneuronal tissues (Hazan et al., 1999; Charvin et al., 2003; Wharton et al., 2003; Karabay et al., 2004). Though Katanin and Spastin share the ability to make internal breaks in microtubules, they only share homology in the AAA region and their NH₂-terminal regions are quite distinct. This might indicate use of distinct adaptor proteins or may indicate different biochemical mechanisms of action.

Whereas the precise role of Spastin in unclear, the disease phenotype where axons of some long neurons degenerate after apparently normal central nervous system development suggests that the microtubule-severing activity may be important in axonal maintenance and that Katanin is not able to compensate for Spastin deficiency in this circumstance. The recent finding that loss of *D. melanogaster* Spastin paradoxically results in decreased microtubule content at the neuromuscular junction with resultant decreases in transmitter release suggests that Spastin may be required for maintenance of axon terminals (Sherwood et al., 2004).

A growing number of neurodegenerative disorders are linked to microtubule function. Mutations in microtubule motors including KIF5a (Reid, 2003) and dynein complex components (Puls et al., 2003) cause hereditary spastic paraplegia and motor neuron degeneration, respectively. Tau, a microtubule-associated protein, is mutated in chromosome 17–linked fronto-temporal dementia and accumulates in neurofibrillary tangles in Alzheimer’s disease (Lee et al., 2001). Abnormalities of microtubule destabilizing enzymes can now be considered capable of contributing to neurodegeneration.

**Materials and methods**

**Production of recombinant Spastin**

HeLa mRNA was prepared using the Oligotex kit (QIAGEN). After performing RT-PCR (Omniscript; QIAGEN), Spastin cDNA was cloned into pGEX6p-3 for production of recombinant protein in *Escherichia coli* or into pEYFP-C1. Mutations were engineered with the QuickChange (Stratagene) kit. GST-Spastin was produced in BL21DE3 pLys or E. coli (RILP cells; Stratagene). LB cultures containing carbencillin, streptomycin, and chloramphenicol were grown at 37°C in an OD₆₀₀ of 1.0. 0.4 mM IPTG and 2% ethanol were added, and the cultures were grown for 48 h at 16°C. Washed cells in 25 ml of lysis buffer (50 mM HEPES/KOH, pH 7.4, 150 mM NaCl, 5 mM MgCl₂, 5% glycerol, and 2 mM ATP) supplemented with an EDTA-free protease inhibitor cocktail (Roche) were lysed with an homogenizer (Emulsiflex model C-5; Avestin) operating in an ice bath at 15,000–20,000 psi. The lysate was adjusted to 1% Triton X-100 and cen-
trifuged (Ti60 rotor [Beckman Coulter]; 50,000 rpm, for 50 min, at 4°C) and pumped over a 1-ml glutathione-Sepharose column [Amersham Biosciences]. After washing with 10 volumes of lysis buffer containing 500 mM NaCl and 20 volumes of lysis buffer containing 0.1% Triton X-100, 150 mM NaCl and lacking ATP, Spastin was eluted using a linear gradient of 0–20 mM glutathione in enzyme buffer (50 mM Hepes, 150 mM NaCl, 5 mM MgCl₂, 5% glycerol, and 0.1% Triton X-100). In some cases, Spastin was further purified by binding to SP-Sepharose (1 ml HitTrap col-
umn) and eluted with 500 mM NaCl in enzyme buffer. The GST moiety was removed with Precision Protease [Amersham Biosciences].

Malachite green ATPase assay
ATPase activity was measured using the malachite green colorimetric assay using sodium phosphate as a standard. Reactions (typically 20 μl) containing the concentrations of enzyme and ATP indicated in the figures were incubated at 37°C for the times indicated in the figures. Next, the absorbance (OD₅₇₀nm) was recorded. Finally, the absorbances of control samples containing the same amount of ATP, but lacking the enzyme, were subtracted from all values.

Transfection, cell culture, and immunofluorescence
TC7 or NIH 3T3 cells stably transfected with GFP-tubulin were maintained in DME supplemented with 10% FCS, penicillin, and streptomycin at 37°C with 5% CO₂. For transient transfections, cells were grown on coverslips in 12-well dishes and transfected with YFP-Spastin constructs using Transfectin (Bio-Rad Laboratories). After 24–48 h, cells were rinsed and fixed with methanol for 5 min at −20°C. Cells were blocked in TBS containing 10% normal donkey serum and 0.2% Triton X-100 for 1 h at room temperature. Anti-tubulin antibody (YLI/2 [Chemicon] or anti-Glu-tubulin [Gundersen et al., 1984] 1:500 dilution) was diluted in blocking buffer (PBS, 10% normal goat serum, and 0.1% Triton X-100). After incubation for 2 h at room temperature, the secondary antibody (Cy-3- or Cy-5–labeled donkey anti-rat; Jackson Immunoresearch Laboratories) was applied for 1 h at 25°C. Still images were obtained using an Optiphot (Nikon) with a 60× objective. Photographs were obtained using a cooled CCD camera (Princeton Instruments) and processed using Metamorph software.

Microtubule-severing assay in permeabilized cells
TC7 or NIH 3T3 cells were rinsed three times in prewarmed PEM buffer at 37°C on a heating block, and then were permeabilized by addition of prewarmed PEM containing 0.2% Triton X-100 for 60 s. After aspiration, the microtubules in the permeabilized cells were stabilized by addition of PEM containing 10 μM taxol. Cells were rinsed in PEM/taxol, and all further manipulations were performed at 37°C.

For severing reactions, recombinant Spastin in enzyme buffer was diluted to 80 nM in PEM buffer. This mixture was added to cells and reactions were initiated by adding ATP to 0.25 mM or the concentration indicated in the figures. Reactions were stopped by removal of the enzyme and fixation in cold methanol. Microtubule content was assessed either by immunofluorescence or real-time imaging of GFP-tubulin.

Imaging E442Q Spastin bound to microtubules
Unlabeled microtubules were immobilized on kinesin-coated coverslips as described in the preceding paragraph and perfused with 100 nM GST-E442Q Spastin or 100 nM GST alone. After 5 min of binding, chambers were washed three times and fixed for 3 min at 25°C with 1% glutaraldehyde. Samples were stained for tubulin [Tyr-tubulin-specific antibody] and for GST [Amersham Biosciences].

Time-lapse video microscopy
Cells or perfusion chambers were transferred to a microscope (model TE300; Nikon), equipped with a heated (34°C) chamber and a 60× (1.4 NA) plan apo lens, Epifluorescence images were collected with a camera (model CoolSnap HQ; Roper Scientific). The exposure time was controlled with a Lambda 10–2 filter changer (Sutter Instruments) driven by Meta- morph (Universal Imaging Corporation). Images were processed with a low-pass filter.

Microtubule binding assay
Microtubules were assembled by incubating tubulin (Cytoskeleton, Inc.) at 0.2 mg/ml in PEM buffer with 1 mM GTP and 20 μM taxol for at least 1 h at 37°C. 5 μl of microtubules was added to each reaction containing recombinant 1 μg WT or mutant Spastin and ATP as indicated in the figures. Reactions were performed in PEM buffer, and the final volume was 50 μl. After 10 min at 37°C, microtubules were separated from soluble tubulin by ultracentrifugation (TY100 rotor [Beckman Coulter], run at 50,000 rpm for 10 min, 37°C, 100,000 gₑ). Equal portions of pellet and supernatant fractions were analyzed by SDS-PAGE.

Online supplemental material
Fig. S1 shows Spastin-mediated severing in permeabilized TC7 cells. Fig. S2 shows that recombinant E442Q Spastin binds along the length of purified microtubules. Five videos are available online (Videos 1–5). In Videos 1–3 microtubules in permeabilized NIH 3T3 cells stably expressing GFP-tubulin were imaged in real time. Video 1 shows a cell incubated with WT Spastin; Video 2 shows a region of detail from the cell imaged in Video 1; and Video 3 shows a cell incubated with mutant Spastin. The complete videos for the data in Fig. 3 are shown in Videos 4 and 5. Video 4 shows incubations with WT enzyme, whereas Video 5 shows an incubation with mutant E442Q Spastin. Legends and methods for the videos are available online at http://www.jcb.org/cgi/content/full/jcb.200409058/DC1.

We thank our colleague Dr. Richard Vallee for suggesting the use of permeabilized cells, and Dr. Susan Gilbert (University of Pittsburgh) for giving us helpful advice and the gift of recombinant kinesin and expression constructs.

This work was supported by the Paul Beeson Physician Faculty Scholars Program (to B.P. Lauring) and by grants from the National Institutes of Health (to B.P. Lauring and G.G. Gundersen) and the Dystonia Medical Research Foundation (to B.P. Lauring). E. R. Gomes was supported by Fundação para a Ciência e Tecnologia of Portugal.

Submitted: 10 September 2004
Accepted: 22 December 2004

References

Ahmad, F.J., F. Yu, F.J. McNally, and P.W. Baas. 1999. An essential role for katanin in severing microtubules in the neuron. J. Cell Biol. 145:305–315.

Antonsson, B., D.B. Kassel, G. Di Paolo, R. Lutjens, B.M. Riederer, and G. Gremmeling. 1998. Identification of in vitro phosphorylation sites in the growth cone protein SCG10. Effect of phosphorylation site mutants on microtubule-destabilizing activity. J. Biol. Chem. 273:8439–8446.

Babst, M., T.K. Sato, L.M. Banta, and S.D. Emr. 1997. Endosomal transport function in yeast requires a novel AAA-type ATPase. Vps4p. EMBO J. 16:1820–1831.

Babst, M., B. Wendland, E.J. Estepa, and S.D. Emr. 1998. The Vps4p AAA ATPase regulates membrane association of a Vps protein complex required for normal endosome function. EMBO J. 17:2982–2993.

Bhattacharya, R., and F. Cabral. 2004. A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol. Biol. Cell. 15:3123–3131.

Cashkar, A.G., E.C. Schirmer, D.A. Hattendorf, J.R. Glover, M.S. Ramakrishnan, D.M. Ware, and S.L. Lindquist. 2002. Defining a pathway of communication from the C-terminal peptide binding domain to the N-terminal ATPase domain in a AAA protein. Mol. Cell. 9:751–760.

Charvin, D., C. Cifuentes-Diaz, N. Fonknechten, V. Joshi, J. Hazan, J. Melki, and S. Bettegu. 2003. Mutations of SPG4 are responsible for a loss of function of spastin, an abundant neuronal protein localized in the nucleus. Hum. Mol. Genet. 12:71–78.

Ciccarelli, F.D., C. Proukakis, H. Patel, H. Cross, S. Azam, M.A. Patton, P. Bork, and A.H. Crosby. 2003. The identification of a conserved domain in both spartin and spastin, mutated in hereditary spastic paraplegia.
Dalal, S., M.F. Rosser, D.M. Cyr, and P.J. Hanson. 2004. Distinct roles for the AAA ATPases NSF and p97 in the secretory pathway. *Mol. Biol. Cell.* 15:637–648.

Errico, A., A. Ballabio, and E.I. Rugarli. 2002. Spastin, the protein mutated in autosomal dominant hereditary spastic paraplegia, is involved in microtubule dynamics. *Hum. Mol. Genet.* 11:153–163.

Fink, I.K. 2002. Hereditary spastic paraplegia: the pace quickens. *Ann. Neurol.* 51:669–672.

Fonknechten, N., D. Mavel, P. Byrne, C.S. Davoine, C. Cruaud, D. Boentsch, D. Samson, P. Coutinho, M. Hutchinson, P. Moncagle, et al. 2000. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. *Hum. Mol. Genet.* 9:637–644.

Frickey, T., and A.N. Lupas. 2004. Phylogenetic analysis of AAA proteins. *J. Struct. Biol.* 146:2–10.

Frohlich, K.U. 2001. An AAA family tree. *J. Cell Sci.* 114:1601–1602.

Gundersen, G.G., M.H. Kalnonski, and J.C. Bulinski. 1984. Distinct populations of microtubules: tyrosinated and nontyrosinated alpha tubulin are distributed differently in vivo. *Cell.* 38:779–789.

Hartman, J.J., and R.D. Vale. 1999. Microtubule disassembly by ATP-dependent oligomerization of the AAA enzyme katanin. *Science.* 286:782–785.

Hartman, J.J., J. Mahr, K. McNally, K. Okawa, A. Iwamatsu, S. Thomas, S. Cheesman, J. Heuser, R.D. Vale, and F.J. McNally. 1998. Katanin, a microtubule-severing protein, is a novel AAA ATPase that targets to the centrosome using a WD40-containing subunit. *Cell.* 93:277–287.

Hazan, J., N. Fonknechten, D. Mavel, C. Paternotte, D. Samson, F. Artiguenave, C.S. Davoine, C. Cruaud, A. Durr, P. Wincker, et al. 1999. Spastin, a novel AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. *Nat. Genet.* 23:296–303.

Infante, A.S., M.S. Stein, Y. Zhai, G.G. Borisy, and G.G. Gundersen. 2000. Detyrosinated (Glu) microtubules are stabilized by an ATP-sensitive plus-end cap. *J. Cell Sci.* 113:3907–3919.

Karabay, A., W. Yu, J.M. Solowska, D.H. Baird, and P.W. Baas. 2004. Axonal growth is sensitive to the levels of katanin, a protein that severs microtubules. *J. Neurosci.* 24:5778–5788.

Klumpp, L.M., K.M. Brendza, J.M. Rosenberg, A. Hoenger, and S.P. Gilbert. 2003. Motor domain mutation traps kinesin as a microtubule rigor complex. *Biochemistry.* 42:2595–2606.

Lee, V.M., M. Goedert, and J.Q. Trojanowski. 2001. Neurodegenerative tauopathies. *Annu. Rev. Neurosci.* 24:1121–1159.

Lindsey, J.C., M.E. Luscher, C.J. McDermott, K.D. White, E. Reid, D.C. Rubinstein, R. Bashir, J. Hazan, P.J. Shaw, and K.M. Bushby. 2000. Mutation analysis of the spastin gene (SPG4) in patients with hereditary spastic paraparesis. *J. Med. Genet.* 37:759–765.

Martin, L., M.L. Fanaragga, K. Aloria, and J.C. Zabala. 2000. Tubulin folding cofactor D is a microtubule destabilizing protein. *FEBS Lett.* 470:93–95.

Matveeva, E., and S.W. Whiteheart. 1998. The effects of SNAP/SNARE complexes on the ATPase of NSF. *FEBS Lett.* 435:211–214.

McNally, F.J., and R.D. Vale. 1993. Identification of katanin, an ATPase that severs and disassembles stable microtubules. *Cell.* 75:419–429.

McNally, F.J., and S. Thomas. 1998. Katanin is responsible for the M-phase microtubule-severing activity in *Xenopus* eggs. *Mol. Biol. Cell.* 9:1847–1861.

Nicolai, M., C. Lasbleiz, and J.M. Dura. 2003. Gain-of-function screen identifies a role of the Sec7d oncogene in *Drosophila* mushroom body development. *J. Neurobiol.* 57:291–302.

Ogura, T., and A.J. Wilkinson. 2001. AAA+ superfamily ATPases: common structure–diverse function. *Genes Cells.* 6:575–597.

Ogura, T., S.W. Whiteheart, and A.J. Wilkinson. 2004. Conserved arginine residues implicated in ATP hydrolysis, nucleotide-sensing, and inter-subunit interactions in AAA and AAA+ ATPases. *J. Struct. Biol.* 146:106–112.

Puls, I., C. Jonnakuty, B.H. LaMonte, E.L. Holzbaur, M. Tokito, E. Mann, M.K. Floeter, K. Bidaus, D. Drayna, S.J. Oh, et al. 2003. Mutant dynactin in motor neuron disease. *Nat. Genet.* 33:455–456.

Reid, E. 2003. Science in motion: common molecular pathological themes emerge in the hereditary spastic paraplegias. *J. Med. Genet.* 40:81–86.

Reid, E., J. Connell, T.L. Edwards, S. Duley, S.E. Brown, and C.M. Sanderson. 2005. The hereditary spastic paraplegia protein spastin interacts with the ESCRT-III complex-associated endosomal protein CHMP1B. *Hum. Mol. Genet.* 14:19–38.

Sarria, A.J., J.G. Lieber, S.K. Nordean, and R.M. Evans. 1994. The presence or absence of a vimentin-type intermediate filament network affects the shape of the nucleus in human SW-13 cells. *J. Cell Sci.* 107:1593–1607.

Schirmer, E.C., C. Queitsch, A.S. Kowal, D.A. Parsell, and S. Lindquist. 1998. The ATPase activity of Hsp104, effects of environmental conditions and mutations. *J. Biol. Chem.* 273:15546–15552.